Zhong Guo Zheng Quan Bao - Zhong Zheng Wang·2025-12-01 23:22Overview - Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced that its subsidiary, Shanghai Fuhong Hanlin Biotechnology Co., Ltd., received approval from the National Medical Products Administration for clinical trials of HLX37 injection, a bispecific antibody for treating advanced/metastatic solid tumors [2][3]. Group 1 - HLX37 is a recombinant humanized bispecific antibody targeting PD-L1 and VEGF, developed for the treatment of advanced/metastatic solid tumors. Preclinical studies indicate that HLX37 can inhibit tumor growth and has good safety profiles [3]. - As of October 2025, the cumulative R&D investment in HLX37 by the group is approximately RMB 50.23 million (unaudited) [3]. - According to IQVIA MIDASTM data, the global sales of PD-1/PD-L1 and VEGF bispecific antibody products are projected to be around USD 920 million in 2024, with the first product expected to be approved in May 2024 [3].